CXCL2/CXCL8 Promote Intervertebral Disc Degeneration

Last updated: July 28, 2023
Sponsor: Zhongda Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

CXCL2/CXCL8

Clinical Study ID

NCT05976516
20220224016
  • All Genders

Study Summary

Low back pain (LBP) is the largest cause of morbidity in the world, and about 80% of Chinese people are affected in their lifetime. Although the prevalence of IDD gradually increases with age, IDD is very common among subjects under 30 years old. In addition to age, there are other factors, such as excessive or uneven mechanical load, obesity, genetics, nutrition, trauma and gender. In addition, it is not clear whether the heavy physical load associated with occupation is an important risk factor for IDD. Some studies have found that IDD is more common among athletes than the general population. Due to the complexity and multifactorial nature of IDD, its pathogenesis and risk factors are still unclear, which seriously hinders the rational stratification of LBP patients and limits the development of personalized treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • It meets the diagnostic criteria of lumbar disc degeneration; No previous history ofspinal surgery; Good ability of independent behavior and cooperation in completingresearch; The patient is aware of this study and has signed the consent form.

Exclusion

Exclusion Criteria:

  • Patients with spinal tumor, infection, tuberculosis and other diseases; Patients withclaustrophobia; Parkinson's syndrome patients; Poor cooperation, Poor image quality;Patients with osteoporosis.

Study Design

Total Participants: 40
Treatment Group(s): 1
Primary Treatment: CXCL2/CXCL8
Phase:
Study Start date:
August 01, 2023
Estimated Completion Date:
March 30, 2024

Connect with a study center

  • Zhongda Hospital

    Nanjing, Jiangsu
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.